Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Framingham, MA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $444. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -9221.4%. Its beta of 4.03 implies it has historically moved more than the broad market.
Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Arch Therapeutics, Inc. is most often compared with the following Healthcare names: